Pricing Log in Create free account
Friday 6 November 2026 Export RGEN’s income statement to Excel — free account

Repligen Corporation

RGEN Healthcare Medical Instruments & Supplies

Repligen Corporation’s revenue for fiscal 2025 (year ended December 2025) was $738.3 million, up 16.4% from fiscal 2024.

Revenue
+10.9%
EPS
−351.9%
Free cash flow
−11.5%
Total debt
+3.28%

Quarter to September 2026, against a year earlier

172.52 4.04 +2.40%
Market cap
$10.8B
P/E
0.0×
Fwd P/E
−615×
Dividend yield
—
F-score
6/9
Altman Z
7.49
Beneish M
−2.52
Dividend safety
n/a
Overview Business Profile Earnings & Analysis
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios
Segments Valuation Filings

Repligen Corporation 10-Q filed Oct 30, 2026

Fiscal Q3 2026 · Period ended Sep 30, 2026 · Filed · accepted 4:01 PM ET · Document on sec.gov · Filing index

Red flags

  • Material weakness

    Repligen Corporation’s 10-Q reports a material weakness in internal control over financial reporting

    Except for the material weaknesses described above, there have been no changes in our internal control over financial reporting

    10-Q filed · The filing · sec.gov

  • Share dilution

    Shares outstanding rose 13.6% in a year, to 63.9 million

    10-Q filed · The filing · sec.gov

What changed

Part I, Item 2, Management’s Discussion and Analysis Part II, Item 1A, Risk Factors
Previous quarter Same quarter last year

Part I, Item 2, Management’s Discussion and Analysis, against the 10-Q filed Jul 29, 2026: 6 added · 6 removed · 24 modified; 11 with only figures updated; 1 moved without change

  1. Modified · Acquisitions

    On July 21October 6, 2026, we entered into an Agreement and Plan completed our previously announced acquisition of Merger (the “Merger Agreement”) to acquire all of the outstanding shares of common stock of BioLife Solutions, Inc. (“BioLife”), a publicly traded company focused on developing cell processing tools and services for the cell and gene therapy market, for approximately $1.51.9 billion, comprised of approximately 64% 7.2 million shares in our common stock and 36% approximately $564 million in cash (on hand. Following the acquisition, BioLife operates as our wholly owned subsidiary under the name “Transaction”)BioLife Solutions, LLC. We will account for the acquisition in the period the Transaction closes” BioLife brings a differentiated portfolio of products including a market-leading bio- preservation media platform and other cell processing tools, which closing is expected to occur expanding our presence in the cell therapy market. We will account for the acquisition in the fourth quarter of 2026. We expect that the cash portion of the merger consideration will be funded with cash and cash equivalents See Note 14, “Subsequent Events,” included in Part I, Item 1, “Financial Statements,” in this Quarterly Report on handForm 10-Q.